Abstract:Background Osteoporosis (OP) is a systemic metabolic bone disease characterized by decreased bone mass and destruction of bone microstructure, which tends to result in enhanced bone fragility and related fractures. The postmenopausal osteoporosis (PMOP) has a relatively high proportion, and numerous studies reveal that estrogen-deficiency is related to the imbalance of gut microbiota (GM), impaired intestinal mucosal barrier function and enhanced inflammatory reactivity. However, the underlying mechanisms remain unclear and the existing interventions are also scarce. Methods In this study, we established a mouse model induced by ovariectomy (OVX) and conducted fecal microbiota transplantation (FMT) by gavage every day for 8 weeks. Subsequently, the bone mass and microarchitecture of mice were evaluated by the micro computed tomography (Micro-CT). The intestinal permeability, pro-osteoclastogenic cytokines expression, osteogenic and osteoclastic activities were detected by the immunohistological analysis, histological examination, enzyme-linked immunosorbent assay (ELISA) and western blot analysis accordingly. Additionally, the composition and abundance of GM were assessed by 16S rRNA sequencing and the fecal short chain fatty acids (SCFAs) level was measured by metabolomics. Results Our results demonstrated that FMT inhibited the excessive osteoclastogenesis and prevented the OVX-induced bone loss. Specifically, compared with the OVX group, FMT enhanced the expressions of tight junction proteins (zonula occludens protein 1 (ZO-1) and Occludin) and suppressed the release of pro-osteoclastogenic cytokines (tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β)). Furthermore, FMT also optimized the composition and abundance of GM, and increased the fecal SCFAs level (mainly acetic acid and propionic acid). Conclusions Collectively, based on GM-bone axis, FMT prevented the OVX-induced bone loss by correcting the imbalance of GM, improving the SCFAs level, optimizing the intestinal permeability and suppressing the release of pro-osteoclastogenic cytokines, which may be an alternative option to serve as a promising candidate for the prevention and treatment of PMOP in the future. The translational potential of this article This study indicates the ingenious involvement of GM-bone axis in PMOP and the role of FMT in reshaping the status of GM and ameliorating the bone loss in OVX-induced mice. FMT might serve as a promising candidate for the prevention and treatment of PMOP in the future.

Linking the relation between gut microbiota and glucocorticoid-induced osteoporosis

The epidemiological investigation on glucocorticoid-induced osteoporosis

From gut to bone: deciphering the impact of gut microbiota on osteoporosis pathogenesis and management

Modulation of bone remodeling by the gut microbiota: a new therapy for osteoporosis

Gut Microbiota Modulates Osteoclast Glutathione Synthesis and Mitochondrial Biogenesis in Mice Subjected to Ovariectomy

Navigating the gut-bone axis: The pivotal role of Coprococcus3 in osteoporosis prevention through Mendelian randomization

Perturbations in gut microbiota composition in osteoporosis: a systematic review and meta-analysis

Microbiota and Resveratrol: How Are They Linked to Osteoporosis?

Anti-osteoporotic drugs affect the pathogenesis of gut microbiota and its metabolites: a clinical study

The regulative effect and repercussion of probiotics and prebiotics on osteoporosis: involvement of brain-gut-bone axis

Glucocorticoid-induced loss of beneficial gut bacterial extracellular vesicles is associated with the pathogenesis of osteonecrosis

Targeting the gut microbiota-related metabolites for osteoporosis: the inextricable connection of gut-bone axis

Living Probiotic Biomaterials for Osteoporosis Therapy

Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis

The Interplay between Immune System and Microbiota in Osteoporosis

Gut Microbiota in Primary Osteoporosis: a Systematic Review

The Critical Role of T Cells in Glucocorticoid-Induced Osteoporosis

Fecal microbiota transplantation ameliorates bone loss in mice with ovariectomy-induced osteoporosis via modulating gut microbiota and metabolic function

Glucocorticoid-induced Expansion of Classical Monocytes Contributes to Bone Loss

When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis

The role of gut microbiota in bone homeostasis